Cell free fetal DNA to triage antenatal rhesus immune globulin: Is it really cost‐effective in the United States?

To compare the efficacy and costs of three different strategies of antenatal rhesus immune globulin (RhIG) administration in a US population.A decision tree analysis was undertaken for universal antenatal RhIG administration based on RhD serologic paternity testing, universal administration without paternity, and selective antenatal RhIG administration using cell free fetal DNA (cfDNA) for RHD fetal typing. Rates of alloimmunization were...